iNCOVACC

Bharat Biotech’s intranasal vaccine, BBV154 or Incovacc is the world’s first intranasal vaccine to be approved as a booster dose for COVID-19.

  • The nasal vaccine is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein.
  • As the vaccine is given nasally, it triggers an immune response in the mucosal membrane.
  • BBV154 may produce local antibodies in the upper respiratory tract which may provide the potential to reduce infection and transmission.
  • This is the second heterologous booster to be included in the vaccination programme after ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

Current Affairs